Coya Therapeutics, Inc.
Coya Therapeutics, Inc. (Nasdaq Capital Market) is a clinical-stage biotechnology company focused on developing proprietary therapies designed to enhance the function of regulatory T cells, or Tregs, which are immune cells that suppress inflammatory responses and maintain immune homeostasis. The company's research… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Coya Therapeutics, Inc. does
In the company’s own words
Coya Therapeutics, Inc. (Nasdaq Capital Market) is a clinical-stage biotechnology company focused on developing proprietary therapies designed to enhance the function of regulatory T cells, or Tregs, which are immune cells that suppress inflammatory responses and maintain immune homeostasis. The company's research builds on foundational discoveries in Treg biology, including work by Dr. Shimon Sakaguchi, the 2025 Nobel Prize winner in Physiology or Medicine and a member of Coya's Scientific Advisory Board.
The company operates three distinct therapeutic modalities: Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Coya's lead asset, COYA 302, is a biologic combination of low-dose interleukin-2 and CTLA4-Ig designed for subcutaneous administration. The company is advancing COYA 302 through clinical development for amyotrophic lateral sclerosis and frontotemporal dementia, with the FDA accepting investigational new drug applications for both indications. In December 2025, Coya commenced dosing patients in the ALSTARS Phase 2 trial for ALS, with enrollment expected to complete in the second half of 2026. The company also announced FDA acceptance of an IND application for COYA 302 in frontotemporal dementia in January 2026, building on positive results from an investigator-initiated proof-of-concept study.
Additional pipeline candidates include COYA 303, a combination of low-dose IL-2 and a glucagon-like-peptide-1 receptor agonist for inflammatory diseases, and COYA 201, an allogeneic Treg-derived exosome product candidate. Coya's research focuses on neurodegenerative, autoimmune, and metabolic diseases where Treg dysfunction is believed to drive pathology.
The company has established strategic collaborations, including a partnership with Dr. Reddy's Laboratories on COYA 302 for ALS and sponsored research agreements with Houston Methodist Hospital. As of December 31, 2025, Coya had accumulated losses of $62.0 million and reported net losses of $21.2 million for the year. The company website is www.coyatherapeutics.com.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- HOUSTON, TX
- Fiscal year end
- December
- CIK
- 1835022
- SIC
- 2834
Financial performance, year by year
Fiscal 2022–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Coya Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Coya Therapeutics, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Coya Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Coya Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Coya Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Coya Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”